AffiAB®​ Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180)

Specifications

Technique
Antibody

Description

Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293) . This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 0.98 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

Additional Attributes

Host
Human
Isotype
IgG1
Technique
Antibody
Brand
AffiAB